Lipocine Inc
LPCN3.200USD
+0.050+1.59%
Market hours （ET）Quotes delayed by 15 min
17.12MMarket Cap
LossP/E TTM
More Details of Lipocine Inc Company
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. It is exploring partnering opportunities for LPCN 1107, for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, for treatment of non-cirrhotic NASH. Its product candidate, TLANDO, an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
Company Info
Ticker SymbolLPCN
Company nameLipocine Inc
IPO dateMar 21, 2014
CEODr. Mahesh V. Patel, Ph.D.
Number of employees16
Security typeOrdinary Share
Fiscal year-endMar 21
Address675 S Arapeen Dr Ste 202
CitySALT LAKE CITY
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code84108-1295
Phone18019947383
Websitehttps://www.lipocine.com/
Ticker SymbolLPCN
IPO dateMar 21, 2014
CEODr. Mahesh V. Patel, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.05K
+1.52%
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
40.80K
--
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.41K
+11.54%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.07K
+44.84%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Dr. Jill M. Jene, Ph.D.
Dr. Jill M. Jene, Ph.D.
Independent Director
Independent Director
--
--
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.05K
+1.52%
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
40.80K
--
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.41K
+11.54%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.07K
+44.84%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
4.23%
Patel (Mahesh V)
2.04%
BlackRock Institutional Trust Company, N.A.
1.67%
Geode Capital Management, L.L.C.
1.10%
Higuchi (John W)
0.76%
Other
90.20%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
4.23%
Patel (Mahesh V)
2.04%
BlackRock Institutional Trust Company, N.A.
1.67%
Geode Capital Management, L.L.C.
1.10%
Higuchi (John W)
0.76%
Other
90.20%
Shareholder Types
Shareholders
Proportion
Investment Advisor
6.79%
Individual Investor
2.95%
Investment Advisor/Hedge Fund
2.16%
Hedge Fund
0.72%
Research Firm
0.05%
Other
87.32%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
44
678.23K
12.68%
-42.35K
2025Q1
65
678.55K
12.68%
-110.89K
2024Q4
72
645.33K
12.07%
-219.30K
2024Q3
75
703.77K
13.16%
-136.61K
2024Q2
79
690.86K
12.92%
-132.01K
2024Q1
82
639.82K
12.02%
-214.82K
2023Q4
86
649.80K
12.29%
-222.39K
2023Q3
91
667.07K
12.61%
-176.35K
2023Q2
93
641.50K
12.32%
-239.33K
2023Q1
97
745.08K
14.31%
-142.00K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
226.28K
4.23%
+4.82K
+2.18%
Mar 31, 2025
Patel (Mahesh V)
109.05K
2.04%
+1.63K
+1.52%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
89.27K
1.67%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
58.83K
1.1%
+1.37K
+2.38%
Mar 31, 2025
Higuchi (John W)
40.80K
0.76%
--
--
Mar 31, 2025
Susquehanna International Group, LLP
38.98K
0.73%
+13.97K
+55.89%
Mar 31, 2025
Renaissance Technologies LLC
37.51K
0.7%
+1.48K
+4.10%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
24.93K
0.47%
+4.42K
+21.54%
Mar 31, 2025
State Street Global Advisors (US)
18.63K
0.35%
--
--
Mar 31, 2025
Northern Trust Investments, Inc.
13.16K
0.25%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
Date
Type
Ratio
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
